The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - The U.S. FDA has filed Sarepta Therapeutics’ (SRPT) eteplirsen New Drug Application, starting the clock on a 6-month review of the drug. The FDA will make an … Continue Reading
Read nowInsights - Biopharma investors are in a funny spot. Where small/mid-cap biotech and pharma stocks have been pulling back for over a month now, the broader markets … Continue Reading
Read nowInsights - Following the release of minutes from the Fed’s July Open Market Committee (FOMC) meeting on Wednesday, U.S. markets opened lower and continued lower in early … Continue Reading
Read nowResearch - FDA confirms that LDL-C remains a viable surrogate endpoint for cholesterol-lowering drugs. ETC-1002 does not need a cardiovascular outcomes study prior to approval, and -1002 should be … Continue Reading
PremiumResearch - It’s been “risk-off” in equities this week as traders begin to factor in a rate hike from the Fed, and the high-beta biotech sector has … Continue Reading
Read nowResearch - On Affimed's trial delay and Marinus' three-month performance.
PremiumResearch - Second phase III trial confirms drug profile of plecanatide, allaying any fears that the low diarrhea rate in the first phase III was a fluke. With … Continue Reading
Premium
